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March 2011704 Arthurs et allaparotomy, reduces length of bowel resection, and limits
acute renal and pulmonary failure. Most important, suc-
cessful endovascular therapy portends a survival advantage
in this moribund population.
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undergo endovascular therapy first. Given the retrospective nature,
trying to differentiate the reasons for selection bias was very
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Dr Sean P. Roddy (Albany, NY ). I would like to congratu-
late Dr Arthurs and his colleagues at the Cleveland Clinic on an
excellent presentation and an excellent manuscript. They have
challenged the concept of immediate revascularization and man-
datory second-look laparotomy. I have four questions.
First, 81% of the patients who presented were treated with
endovascular therapy. Can you explain any reason—surgeon pref-
erence, physical exam, diagnostic angiographic findings, et ce-
tera—why the 19% were treated immediately with traditional sur-
gery?
Second, you employed thrombolytic therapy in half the pa-
tients and then continued an infusion for several days in 40% of this
subset. Did that subset have any difference in the need for laparot-
omy or the amount of bowel resected than the other groups? In
essence, did the time dedicated to the infusion therapy patients
result in an identifiable increase in morbidity?
Third, you were very aggressive with endovascular therapy in
this patient population but saw no overall decrease in mortality
compared with open surgery, as we might expect. Do you think
that this aggressive stance and time in the angiography suite, which
averaged 2 hours, raised the mortality overall in both treatment
arms? Do you think that converting to open surgery earlier may
have benefited both groups and not just the comparison between
the two?
Fourth and lastly, the majority of failures were in the embolus
patients. Do you believe that these patients are best treated with
open surgery, or are there subsets that you identified that can be
effectively managed with endovascular therapy?
Dr Zachary M. Arthurs. The first question is addressing the
selection bias. Eighty-one percent of the patients were chosen toifficult. The only aspect that really made the two groups disparate
as the etiology. The etiology, thrombotic vs embolic, was typi-
ally diagnosed in the operative suite or based on the computed
omography angiography. I thought that may have been a predis-
osing factor; however, it is not the case. Examining all measurable
ovariates, we couldn’t differentiate any specific reasons for bias
ther than surgeon preference. Is it a staff preference? I think
aybe early on it probably was; but today, it is departmental
reference.
The second aspect was if the patient underwent infusion
herapy and if infusion therapy extended 1 day or beyond, did it
ut them at a higher risk in regards to morbidity and mortality?
valuating the numbers, 56 patients underwent endovascular ther-
py altogether, 48%, or 28 patients, underwent lytic therapy. The
ajority of our patients received 1 day of therapy, and then there
re about seven patients that received 2 or more days of infusion
herapy. When we examined the mortality for those patients, there
s a trend for worse outcomes if they undergo infusion therapy
onger. These subgroups are really too small to draw any conclu-
ions; however, the mortality is 40% to 45%. And as well, did it
hange their laparotomy rate? Their laparotomy rate was around
8% to 72% in all of those subgroups.
The third question, if we converted to open sooner would it
ave changed the mortality in both groups? I think that avoiding
he insult of the laparotomy does give the opportunity to spare
ore bowel. Our median time to laparotomy was 4 hours; there-
ore, most of these patients are revascularized with endovascular
echniques at the time of their initial laparotomy. I don’t think that
mmediate laparotomy would have changed the mortality rate.
And number 4, when you do the subgroup analysis, the
mbolectomy patients appear to have a higher mortality. Again, I
hought that an open therapy would be more advantageous, but I
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if they have a higher mortality rate, but they are also the ones that
presented in the shortest amount of time and with the least amount
of collateralization. I think they are the highest-risk populations.
And so doing the subgroup, I can’t really say if one therapy is going
to be better than the other, but I think that endovascular therapy is
just as good as open therapy.
Dr Julie Ann Freischlag (Baltimore, Md). I think making the
diagnosis of mesenteric ischemia in the hospital is the toughest
diagnosis to make. Whenever we discuss it at morbidity and
mortality conference, it seems our interventions are always late. We
are frequently a day or two late in making the diagnosis, and
therefore, the patients do poorly. So in these patients, if you are
going to do endovascular therapy, which sounds like a great way to
go, how do you decide how long you are going to watch them? Doay lull yourself into feeling great that you revascularized them,
ut you may again wait too long to get them back to exploration.
DrArthurs. It is definitely a heterogeneous group. Currently,
e revascularize the patient and then decide on immediate or
elayed laparotomy. If they have peritonitis, the patient is explored
fter revascularization. If the patient has various degrees of abdom-
nal pain, then exploration is reserved for progression of symptoms.
ost of these patients remain extubated. If they are intubated and
ou can’t follow serial exams, that would be another reason to
onsider an early exploration. I agree with you. Some of these
atients come in very sick and it is clear. Some of them come in and
hey are not sick at all, and those are the patients that received 2 to
days of thrombolytic infusion; and then there are the ones in
etween that you just don’t know. I think if you put them in a
ritical care setting and you closely observe them, understandingthey all go to a laparotomy in 4 hours, or do you try to make a
clinical determination based on their exam? I have a feeling you
that you may have to explore them in the next 6 to 8 hours, it is a
reasonable approach.
COLLECTIONS OF PAPERS
On the Web version of the Journal, selected articles have been grouped together for the convenience of the
readers. The current collections include the following:
American Board of Vascular Surgery
Editorial Comments
History
Reporting Standards
Technical Notes
Basic Science Reviews
Guidelines
Lifeline Research Meeting Abstracts
Reviews
